This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petrelli, F. Articles by Barni, S. Search for Related Content PubMed PubMed Citation Articles by Petrelli, F. Articles by Barni, S.

Breast Cancer

Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era

Division of Medical Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy

Key Words. Metastatic breast cancer • Angiogenesis • Targeted therapies • Tyrosine kinase inhibitors

Correspondence: Fausto Petrelli, M.D., Medical Oncology, Treviglio-Caravaggio Hospital, Treviglio (BG), Italy. Telephone: 39-0363424743; Fax: 39-0363424380; e-mail: faupe{at}libero.it

Disclosure: This article discusses bevacizumab (Genentech), sunitinib (Pfizer), pazopanib (GlaxoSmithKline), mTOR inhibitors (Wyeth/Novartis), and axitinib (AstraZeneca) for the treatment of breast cancer. No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Targeted therapies for breast cancer are evolving rapidly. Trastuzumab has revolutionized breast cancer treatment and outcome, reducing the risk for recurrence and significantly increasing survival, at least for a subgroup of patients. Other targeted therapies, such as bevacizumab, a monoclonal antibody targeting angiogenesis, lapatinib, a dual human epidermal growth factor receptor (HER)-1 and HER-2 inhibitor, other small-molecule tyrosine kinase inhibitors, and mammalian target of rapamycin inhibitors, have been developed in phase II and III clinical trials. Although there has been rapid approval of these new drugs by health authorities, some questions have emerged about their application in clinical practice. What is the appropriate drug or sequence of drugs? What is the ideal target? How should tumor response be evaluated? Are financial resources sufficient to treat patients? How do we design trials with these molecules? These are emerging as current dilemmas for clinical oncologists.

This article has been cited by other articles:

				N. K. Saxena, L. Taliaferro-Smith, B. B. Knight, D. Merlin, F. A. Anania, R. M. O'Regan, and D. Sharma Bidirectional Crosstalk between Leptin and Insulin-like Growth Factor-I Signaling Promotes Invasion and Migration of Breast Cancer Cells via Transactivation of Epidermal Growth Factor Receptor Cancer Res., December 1, 2008; 68(23): 9712 - 9722. [Abstract] [Full Text] [PDF]